Literature DB >> 12747939

Opioids and the apoptotic pathway in human cancer cells.

Ian S Zagon1, Patricia J McLaughlin.   

Abstract

This study was designed to examine the role of opioids in cell survival, with an emphasis on the mechanism of opioid growth factor (OGF, [Met(5)]-enkephalin)-dependent growth inhibition. Using three human cancer cell lines: MIA PaCa-2 pancreatic adenocarcinoma, HT-29 colon adenocarcinoma, and CAL-27 squamous cell carcinoma of the head and neck, and OGF and the opioid antagonist naltrexone (NTX) at a dosage (10(-6)M) selected because it is known to repress or increase, respectively, cell replication, the effects on apoptosis (TUNEL, Annexin V) and necrosis (trypan blue) were investigated on days 2, 5, and 7 of exposure. In addition, the influence of a variety of other natural and synthetic opioids on apoptosis and necrosis was examined at a dosage of 10(-6)M. OGF, NTX, naloxone, [D-Pen(2,5)]-enkephalin, [Leu(5)]-enkephalin, dynorphin A1-8, beta-endorphin, endomorphin-1 and -2, and methadone at concentrations of 10(-6)M did not alter cell viability of any cancer cell line. Exposure of cultures to [D-Ala(2),MePhe(4),Glycol(5)]-enkephalin (DAMGO), morphine, or etorphine at 10(-6)M significantly increased the number of adherent cells positively stained for TUNEL and Annexin V, as well as the number of necrotic cells in the supernatant, from control levels at all time points studied. The effects of DAMGO, morphine, and etorphine on apoptosis/necrosis were not fully blocked by concomitant administration of naloxone. Despite the increase in cell death in some opioid-treated groups, the number of apoptotic and necrotic adherent cells, and the number of necrotic cells in the supernatant, was no more than 1-2% of the total cell population. These results indicate that the inhibitory (OGF) or stimulatory (NTX) action on cell growth in tissue culture is not due to alterations in apoptotic or necrotic pathways. Moreover, although some opioids increased cell death, and dose-effect relationships need to be established, this activity was not of great magnitude and supports the previously reported lack of growth inhibition of many of these compounds.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12747939     DOI: 10.1016/s0143-4179(03)00007-6

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  21 in total

Review 1.  Opioid growth factor and the treatment of human pancreatic cancer: a review.

Authors:  Ian S Zagon; Patricia J McLaughlin
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 2.  Morphine: double-faced roles in the regulation of tumor development.

Authors:  X Y Zhang; Y X Liang; Y Yan; Z Dai; H C Chu
Journal:  Clin Transl Oncol       Date:  2017-11-10       Impact factor: 3.405

3.  Morphine inhibits cell viability and growth via suppression of vascular endothelial growth factor in human oral cancer HSC-3 cells.

Authors:  Tadashi Nishiwada; Yoshitaka Kawaraguchi; Keiko Uemura; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2019-05-02       Impact factor: 2.078

4.  Effects of morphine and fentanyl on 5-fluorouracil sensitivity in human colon cancer HCT116 cells.

Authors:  Yasumitsu Nomura; Yoshitaka Kawaraguchi; Hiroshi Sugimoto; Hitoshi Furuya; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2013-10-05       Impact factor: 2.078

5.  Delta opioid peptide DADLE and naltrexone cause cell cycle arrest and differentiation in a CNS neural progenitor cell line.

Authors:  Shang-Yi Tsai; Chung-Ting Lee; Teruo Hayashi; William J Freed; Tsung-Ping Su
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

Review 6.  Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery?

Authors:  Hidetomo Niwa; David J Rowbotham; David G Lambert; Donal J Buggy
Journal:  J Anesth       Date:  2013-05-14       Impact factor: 2.078

7.  The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.

Authors:  Diego M Avella; Eric T Kimchi; Renee N Donahue; Hephzibah Rani S Tagaram; Patricia J McLaughlin; Ian S Zagon; Kevin F Staveley-O'Carroll
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-18       Impact factor: 3.619

8.  The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.

Authors:  Fan Cheng; Patricia J McLaughlin; Michael F Verderame; Ian S Zagon
Journal:  Mol Biol Cell       Date:  2008-10-15       Impact factor: 4.138

Review 9.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Matthew S Klocek; Ian S Zagon
Journal:  Brain Res Bull       Date:  2009-08-14       Impact factor: 4.077

10.  Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

Authors:  Patricia J McLaughlin; Ian S Zagon; Sunny S Park; Andrea Conway; Renee N Donahue; David Goldenberg
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.